Company Filing History:
Years Active: 2007
Title: Bruce Register: Innovating in Amyloid Research
Introduction
Bruce Register, an innovative inventor based in Berwyn, PA, has made significant contributions to the field of biochemistry through his research and inventions. With one patent to his name, Register's work focuses on developing methods to monitor and inhibit β-secretase activity, a critical enzyme in Alzheimer's disease research.
Latest Patents
Register's patent, titled "Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity," introduces novel methods for identifying inhibitors of β-secretase. This invention utilizes modified β-secretase substrates that have been engineered with altered cleavage sites compared to the wild type. These substrates are designed to enhance the efficiency of β-secretase, thereby making them more susceptible to enzymatic breakdown. Furthermore, the patent includes recombinant polynucleotide molecules encoding these modified substrates and antibodies capable of recognizing the cleavage products.
Career Highlights
Working at Merck & Co., Inc., Register has positioned himself at the forefront of research aimed at understanding and combatting diseases associated with amyloid precursor proteins. His dedication to innovation in this field marks him as a noteworthy figure among contemporary inventors, contributing to the advancement of therapies for Alzheimer's disease.
Collaborations
Bruce Register has collaborated with esteemed colleagues, including Daria Hazuda and Elizabeth Chen Dodson. Working alongside such talented professionals amplifies the impact of his research and paves the way for future advancements in the understanding of β-secretase and its role in neurodegenerative disorders.
Conclusion
In summary, Bruce Register is a distinguished inventor whose work is contributing to critical advancements in the biochemistry of Alzheimer's disease. His patent and ongoing research efforts signify a key step towards innovative solutions in monitoring and inhibiting β-secretase activity. Through his collaborations and work at Merck & Co., Inc., Register continues to lead the way in pioneering research in this vital area of science.